
Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.

Your AI-Trained Oncology Knowledge Connection!


Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.

Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with <em>MET</em> exon 14-mutant non–small cell lung cancer.

Published: May 29th 2020 | Updated:

Published: June 22nd 2017 | Updated: